Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Stopped Enrollment challenges; new batch of drug is being manufactured and there may be additional impetus to reactivate after the analogous Phase 2 study in Japan is completed and those results are made available

Conditions

• Covid19

Interventions

• DRUG: TM5614
• OTHER: Placebo

Sponsor

Northwestern University